Morningstar: Florida Cancer Specialists & Research Institute Among First in Florida to Trial Next-Generation Immunotherapy for Castration-Resistant Prostate Cancer Florida Cancer Specialists & Research Institute Among First in Florida to Trial Next-Generation Immunotherapy for Castration-Resistant Prostate Cancer EurekAlert!: ESMO: 10-year survival data for lung cancer immunotherapy, new PSMA-targeted therapy for recurrent prostate cancer, promising results in metastatic colorectal and urothelial ... ESMO: 10-year survival data for lung cancer immunotherapy, new PSMA-targeted therapy for recurrent prostate cancer, promising results in metastatic colorectal and urothelial ... Investigators from the UCLA Health Jonsson Comprehensive Cancer Center presented new research at the European Society for Medical Oncology (ESMO) Congress, covering advances in immunotherapy, targeted ...
Morning Overview on MSN: Experimental prostate cancer drug shrinks tumors in early clinical trial Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one agent shown to shrink tumors in patients whose disease had resisted every ... A new drug candidate has been developed that simultaneously blocks the proteins regulating cancer growth and metastasis. In animal experiments, when used with immunotherapy, it completely eliminated b ...
